Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A phase 1/2 trial of Daraxonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS is a phase 1/2 interventional study registered as NCT05379985 by Revolution Medicines, Inc., with 754 participants planned, started 2022-05-31 and due to reach its primary completion in 2027-05-31. Interventions recorded: RMC-6236. Conditions listed: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Pancreatic ductal adenocarcinoma.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Colorectal cancer.
- TrialStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma, Colorectal cancer.